NCT03927222 2024-04-08
I-ATTAC
Duke University
Phase 2 Terminated
Clinical Trials
21 trialsNCT00006478 2023-09-18
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Terminated
NCT02978222 2022-12-15
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Marker Therapeutics, Inc.
Phase 2 Terminated
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01174082 2018-06-01
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00005987 2017-11-29
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00477087 2017-11-29
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00001827 2017-10-06
p53 Vaccine for Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00447473 2016-03-17
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00450008 2016-03-17
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00265915 2014-08-12
Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00006113 2014-05-22
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Phase 2 Terminated
NCT01542684 2014-04-30
Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00308087 2013-12-27
PREMIER
Sanofi
Phase 2 Terminated
NCT00104819 2013-08-02
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00033644 2013-04-11
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
GOG Foundation
Phase 2 Terminated
NCT00208975 2012-06-28
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
Emory University
Phase 2 Terminated
NCT00313482 2012-05-11
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
Veeda Oncology
Phase 2 Terminated
NCT00505921 2011-11-16
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00002778 2011-07-20
Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00003561 2011-07-20
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated